<div id="readability-page-1"><p>Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.00) by ($0.22), FiscalAI reports. The business had revenue of $0.12 million for the quarter, compared to the consensus estimate of $1.53 million. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 33.22%.</p><div><p><span></span><span>Get <strong>Celldex Therapeutics</strong> alerts:</span></p></div><h2>Celldex Therapeutics Trading Down 0.6%</h2><p>CLDX stock traded down $0.18 during mid-day trading on Thursday, hitting $30.64. The stock had a trading volume of 1,673,058 shares, compared to its average volume of 781,221. Celldex Therapeutics has a 1-year low of $14.40 and a 1-year high of $31.31. The company has a fifty day moving average of $25.51 and a 200 day moving average of $25.40. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of -9.07 and a beta of 1.24. </p><h2>Celldex Therapeutics News Roundup</h2><p>Here are the key news stories impacting Celldex Therapeutics this week:</p><ul>   <li><span>Positive Sentiment: </span>Celldex completed enrollment in its global Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab for chronic spontaneous urticaria — 1,939 patients across 43 countries (the largest antihistamine-refractory CSU program). This derisks the program and sets up 2026 data catalysts that analysts cite as value drivers. Read More.</li>    <li><span>Positive Sentiment: </span>Stifel Nicolaus reaffirmed a Buy rating and raised its price target to $68 (from $58), implying substantial upside vs. current levels — a bullish institutional signal that can support share price momentum. Read More.</li>    <li><span>Positive Sentiment: </span>Morgan Stanley and other buy-side commentary highlight early EMBARQ enrollment and 2026 data catalysts as underpinning an attractive risk/reward, supporting continued Buy ratings. These analyst endorsements may attract more investor interest ahead of clinical readouts. Read More.</li>    <li><span>Neutral Sentiment: </span>Street consensus remains generally favorable — reported as an average rating of &#34;Moderate Buy&#34; — which suggests mixed but constructive analyst positioning. Read More.</li>    <li><span>Neutral Sentiment: </span>Reported short-interest data for February appears anomalous (shows zero shares), which provides no clear directional signal to traders at this time. Monitor future updates for clarity. </li>    <li><span>Negative Sentiment: </span>Celldex reported Q4/2025 EPS of ($1.22), missing consensus (~($1.00)) and posted revenue of $0.12M vs. ~$1.53M expected; profitability metrics remain deeply negative (very large net margin and negative ROE). These results and weak near-term revenue increase execution risk and pressure valuation until clinical milestones validate potential. Read More.</li> </ul><h2>Wall Street Analyst Weigh In</h2><p>Several analysts have recently weighed in on CLDX shares. Stifel Nicolaus  restated a &#34;buy&#34; rating and issued a $68.00 price objective (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Celldex Therapeutics in a report on Wednesday, January 21st. Finally, Barclays raised their price objective on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the company an &#34;underweight&#34; rating in a research report on Wednesday, December 17th. One investment analyst  has rated the stock with a Strong Buy rating, seven have assigned  a Buy rating, one  has assigned  a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $44.20.</p><p><b>Read Our Latest Research Report on CLDX</b></p><h2>Hedge Funds Weigh In On Celldex Therapeutics</h2><p>Hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its position in  Celldex Therapeutics by 39.3% in the fourth quarter. Wellington Management Group LLP now owns 8,079,608 shares of the biopharmaceutical company's stock worth $219,442,000 after acquiring an additional 2,279,605 shares in the last quarter.  Bellevue Group AG increased its position in  Celldex Therapeutics by 7.6% during the third quarter. Bellevue Group AG now owns 3,557,669 shares of the biopharmaceutical company's stock worth $92,037,000 after buying an additional 250,100 shares during the last quarter.  Commodore Capital LP raised its holdings in  Celldex Therapeutics by 7.8% during the second quarter. Commodore Capital LP now owns 3,450,000 shares of the biopharmaceutical company's stock valued at $70,208,000 after buying an additional 250,000 shares in the last quarter.  State Street Corp lifted its position in shares of  Celldex Therapeutics by 19.5% in the fourth quarter. State Street Corp now owns 3,397,713 shares of the biopharmaceutical company's stock worth $92,282,000 after buying an additional 555,579 shares during the last quarter.  Finally, Braidwell LP boosted its stake in shares of  Celldex Therapeutics by 214.0% during the 4th quarter. Braidwell LP now owns 1,858,109 shares of the biopharmaceutical company's stock worth $50,466,000 after acquiring an additional 1,266,420 shares in the last quarter. </p><h2>Celldex Therapeutics Company Profile</h2> (Get Free Report)<p>Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company's research platforms leverage novel antibody and vaccine technologies designed to engage the patient's immune system, with a particular emphasis on oncology and neurologic indications. Celldex's pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.  </p><p>Among Celldex's lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Celldex Therapeutics</li><li>Read this or regret it forever</li><li>This makes me furious</li><li>The free stock picks nobody’s talking about</li><li>Elon Musk: This Could Turn $100 into $100,000</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Celldex Therapeutics Right Now?</h2><p>Before you consider Celldex Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.</p><p>While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CLDX

<p>Celldex Therapeutics (NASDAQ:CLDX) reported quarterly earnings of ($1.22) EPS, missing estimates of ($1.00) by ($0.22). The company generated $0.12 million in revenue, significantly below the expected $1.53 million. With a negative return on equity of 33.22% and a net margin of -3,446.88%, the results indicate ongoing financial challenges. Despite this, analysts maintain a generally favorable outlook, with a consensus rating of "Moderate Buy" and a price target increase from Stifel Nicolaus to $68, suggesting potential upside for investors.</p>

Celldex Therapeutics (NASDAQ:CLDX) Announces Quarterly Earnings Results